Table 1.
Antidepressants in both study phases
| DEP | PER | OTH | |||||
|---|---|---|---|---|---|---|---|
| Admission | Discharge | Admission | Discharge | Admission | Discharge | ||
| Phase A | SSRI | 108 (29.2%) | 95 (25.7%) | 20 (17.8%) | 19 (17.0%) | 25 (27.2%) | 22 (23.4%) |
| TCA | 67 (18.1%) | 60 (16.2%) | 13 (11.6%) | 15 (13.4%) | 11 (12.0%) | 7 (7.6%) | |
| SNRI | 49 (13.2%) | 82 (22.2%) | 13 (11.6%) | 17 (15.2%) | 11 (12.0%) | 17 (18.5%) | |
| Agomelatine | 25 (6.8%) | 46 (12.4%) | 7 (6.3%) | 13 (11.6%) | 4 (4.3%) | 3 (3.3%) | |
| other AD | 4 (1.0%) | 5 (1.3%) | 2 (1.8%) | 1 (0.9%) | – | – | |
| no AD | 161 (43.5%) | 126 (34.1% | 63 (56.3%) | 55 (49.1%) | 47 (51.1%) | 47 (51.1%) | |
| Phase B | SSRI | 53 (19.2%) | 24 (8.7%) | 23 (28.0%) | 10 (12.2%) | 14 (23.3%) | 9 (15.0%) |
| TCA | 51 (18.5%) | 35 (12.7%) | 13 (15.9%) | 9 (11.0%) | 7 (11.7%) | 5 (8.3%) | |
| SNRI | 34 (12.0%) | 15 (5.4%) | 10 (12.2%) | 8 (9.8%) | 7 (11.7%) | 6 (10.0%) | |
| Agomelatine | 7 (2.5%) | 7 (2.5%) | 3 (3.7%) | 2 (2.4%) | – | – | |
| other AD | 2 (0.7%) | – | – | – | 1 (1.7%) | 1 (1.7%) | |
| no AD | 149 (54.0%) | 204 (74.0%) | 43 (52.4%) | 58 (70.7%) | 38 (63.3%) | 46 (76.7%) | |
Percentages sum to > 100 because some patients were taking more than one AD
SSRI selective serotonin reuptake inhibitors, TCA tri- and tetracyclic AD, SNRI serotonin and norepinephrine reuptake inhibitors, DEP Depression, PER depression with comorbid personality disorder, OTH depression with comorbid other mental disorder